title: SEOM guide to antiemetic prophylaxis in cancer patients treated with chemotherapy 2013.
abstract: Chemotherapy-induced emesis (CIE) both in the form of nausea and vomiting is one of the adverse effects most feared by patients who receive treatment, and one of the factors that most affect their quality of life and limit their functional capacity for everyday activities. Chemotherapy-induced emesis can result from many factors, depending on the treatment and the patients themselves. The best treatment for CIE is prevention, based on the use of drugs aimed at inhibiting the signal of certain neurotransmitters involved in the process. Antiemetic prophylaxis for chemotherapy of high-emetogenous potential lasting 1 day includes a combination of anti-5-HT3, neurokinin-1 inhibitors and dexamethasone. Antiemetic prophylaxis for chemotherapy of moderate-emetogenous potential lasting 1 day includes a combination of palonosetron and dexamethasone. Prophylaxis is not recommended for chemotherapy with minimal emetogenous potential. In the case of unforeseen or refractory emesis the use of olanzapine, metoclopramide or phenothiazine should be considered.
authors.affiliation: Medical Oncology Department, University-Hospital Complex, Orense, Spain, jesus.garcia.gomez@sergas.es.
authors.forename: J
authors.initials: J
authors.lastname: García Gómez
authors.forename: M E
authors.initials: ME
authors.lastname: Pérez López
authors.forename: M
authors.initials: M
authors.lastname: Alonso Bermejo
authors.forename: Y
authors.initials: Y
authors.lastname: Escobar Álvarez
authors.forename: J
authors.initials: J
authors.lastname: García Mata
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018890:Chemoprevention / Q000592:standards*; D004334:Drug Administration Schedule; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D012307:Risk Factors; D014839:Vomiting / Q000139:chemically induced* / Q000517:prevention & control*
chemical_list: D000932:Antiemetics
references.citation: J Clin Oncol. 2011 Apr 10;29(11):1495-501
references.pmid: 21383291
references.citation: Cancer. 2003 Jun 1;97(11):2880-6
references.pmid: 12767103
references.citation: J Clin Oncol. 2005 Feb 20;23(6):1289-94
references.pmid: 15718327
references.citation: Support Care Cancer. 2012 Jul;20(7):1507-14
references.pmid: 21808994
references.citation: J Support Oncol. 2011 Sep-Oct;9(5):188-95
references.pmid: 22024310
references.citation: J Clin Oncol. 2011 Nov 1;29(31):4189-98
references.pmid: 21947834
references.citation: J Clin Oncol. 2005 Apr 20;23(12):2822-30
references.pmid: 15837996
references.citation: Ann Oncol. 2006 Jun;17(6):1000-6
references.pmid: 16524979
references.citation: J Clin Oncol. 2000 Oct 1;18(19):3409-22
references.pmid: 11013282
references.citation: Int J Clin Pract. 2012 Aug;66(8):753-757
references.pmid: 22805267
references.citation: Drugs. 2013 Mar;73(3):249-62
references.pmid: 23404093
references.citation: Support Care Cancer. 2001 Jul;9(5):350-4
references.pmid: 11497388
references.citation: Support Care Cancer. 2007 Nov;15(11):1293-1300
references.pmid: 17436025
references.citation: Ann Oncol. 2012 Aug;23(8):1986-1992
references.pmid: 22396444
references.citation: Cancer Invest. 2000;18(2):163-73
references.pmid: 10705879
references.citation: Support Care Cancer. 2011 Jun;19(6):823-32
references.pmid: 20495832
references.citation: Lancet Oncol. 2009 Feb;10(2):115-24
references.pmid: 19135415
references.citation: J Clin Oncol. 2006 Sep 20;24(27):4472-8
references.pmid: 16983116
references.citation: Support Care Cancer. 2011 Mar;19 Suppl 1:S1-4
references.pmid: 20505956
references.citation: J Clin Oncol. 1997 Jan;15(1):103-9
references.pmid: 8996130
references.citation: J Clin Oncol. 2012 Nov 10;30(32):3998-4003
references.pmid: 22915652
references.citation: Cancer. 2005 Oct 1;104(7):1548-55
references.pmid: 16104039
references.citation: N Engl J Med. 2008 Jun 5;358(23):2482-94
references.pmid: 18525044
references.citation: N Engl J Med. 2000 May 25;342(21):1554-9
references.pmid: 10824073
references.citation: N Engl J Med. 1993 Dec 9;329(24):1790-6
references.pmid: 8232489
references.citation: Support Care Cancer. 2011 Mar;19 Suppl 1:S43-7
references.pmid: 20972805
references.citation: Cancer. 2005 Aug 15;104(4):864-8
references.pmid: 15973669
references.citation: Eur J Pharmacol. 2012 Jun 5;684(1-3):1-7
references.pmid: 22425650
references.citation: J Palliat Med. 2011 Jul;14(7):810-4
references.pmid: 21554125
references.citation: Ann Oncol. 2006 Sep;17(9):1441-9
references.pmid: 16766588
references.citation: Ann Oncol. 2003 Oct;14(10):1570-7
references.pmid: 14504060
references.citation: Support Care Cancer. 2013 Jun;21(6):1655-63
references.pmid: 23314603
references.citation: Support Care Cancer. 2011 Oct;19(10):1609-17
references.pmid: 20835873
references.citation: Ann Pharmacother. 2007 Jan;41(1):68-78
references.pmid: 17200430
references.citation: Expert Rev Anticancer Ther. 2005 Dec;5(6):963-72
references.pmid: 16336087
references.citation: Support Care Cancer. 2011 Oct;19(10):1533-8
references.pmid: 20803345
references.citation: Cancer. 2003 Dec 1;98(11):2473-82
references.pmid: 14635083
references.citation: Ann Oncol. 2007 Feb;18(2):233-40
references.pmid: 17108149
references.citation: Ann Oncol. 2006 Jan;17(1):20-8
references.pmid: 16314401